Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Besides thriving on altered glucose metabolism, cancer cells undergo glutaminolysis to meet their energy demands. As the first enzyme in catalyzing glutaminolysis, human kidney-type glutaminase isoform (KGA) is becoming an attractive target for small molecules such as BPTES [bis-2-(5 phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl sulfide], although the regulatory mechanism of KGA remains unknown. On the basis of crystal structures, we reveal that BPTES binds to an allosteric pocket at the dimer interface of KGA, triggering a dramatic conformational change of the key loop (Glu312-Pro329) near the catalytic site and rendering it inactive. The binding mode of BPTES on the hydrophobic pocket explains its specificity to KGA. Interestingly, KGA activity in cells is stimulated by EGF, and KGA associates with all three kinase components of the Raf-1/Mek2/Erk signaling module. However, the enhanced activity is abrogated by kinase-dead, dominant negative mutants of Raf-1 (Raf-1-K375M) and Mek2 (Mek2-K101A), protein phosphatase PP2A, and Mek-inhibitor U0126, indicative of phosphorylation-dependent regulation. Furthermore, treating cells that coexpressed Mek2-K101A and KGA with suboptimal level of BPTES leads to synergistic inhibition on cell proliferation. Consequently, mutating the crucial hydrophobic residues at this key loop abrogates KGA activity and cell proliferation, despite the binding of constitutive active Mek2-S222/226D. These studies therefore offer insights into ( i ) allosteric inhibition of KGA by BPTES, revealing the dynamic nature of KGA's active and inhibitory sites, and ( ii ) cross-talk and regulation of KGA activities by EGF-mediated Raf-Mek-Erk signaling. These findings will help in the design of better inhibitors and strategies for the treatment of cancers addicted with glutamine metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“T Warburg effect in cancer biology describes the tendency of cancer cells to take up more glucose than most normal cells, despite the availability of oxygen (1, 2).”
BackgroundThe Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088 · cited 4×
“In addition to altered glucose metabolism, glutaminolysis (catabolism of glutamine to ATP and lactate) is another hallmark of cancer cells (2, 3).”
BackgroundInfluentialTargeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · cited 1×
“Because EGF activates the Raf-Mek-Erk signaling module (19), treatment of cells with Mek-specific inhibitor U0126 could block the enhanced KGA activity with parallel inhibition of Erk phosphorylation (Fig.”
BackgroundGao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124 · cited 2×
“It was recently reported that KGA is up-regulated by Myc and Rho and is subjected to ubiquitination (9, 11, 12).”
BackgroundWise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001 · cited 2×
“Inhibition of rat KGA activity by antisense mRNA results in decreased growth and tumorigenicity of Ehrlich ascites tumor cells (7), reduced level of glutathione, and induced apoptosis (8), whereas Myc, an oncogenic transcription factor, stimulates KGA expression and glutamine metabolism (5).”
BackgroundEvidence that glutamine, not sugar, is the major energy source for cultured HeLa cells.
Reitzer, L. J., Wice, B. M., & Kennell, D. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30124-2 · Cited by 1,240
Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells
Le, A., Lane, A. N., Hamaker, M., Bose, S., Gouw, A., Barbi, J., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Zhang, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.009 · Cited by 1,095 · cited 1×
“BPTES selectively suppresses the growth of glioma cells (21) and inhibits the growth of lymphoma tumor growth in animal model studies (22).”
BackgroundTargeting metabolic transformation for cancer therapy
Tennant, D. A., Durán, R. V., & Gottlieb, E. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2817 · Cited by 1,059 · cited 1×
“Next, as cells respond to various physiological stimuli to regulate their metabolism, with many of the metabolic enzymes being the primary targets of modulation (18), we examined whether KGA activity can be regulated by physiological stimuli, in particular EGF, which is important for cell growth and proliferation.”
BackgroundGlutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function
Hu, W., Zhang, C., Wu, R., Sun, Y., Levine, A., & Feng, Z. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001006107 · Cited by 862 · cited 1×
“In comparison, function and regulation of LGA is not well studied, although it was recently shown to be linked to p53 pathway (13, 14).”
BackgroundTargeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation
Wang, J.-B., Erickson, J. W., Fuji, R., Ramachandran, S., Gao, P., Dinavahi, R., Wilson, K. F., Ambrosio, A. L. B., Dias, S. M. G., Dang, C. V., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.009 · Cited by 821 · cited 3×
“(11) reported a small molecule that targets glutaminase activity and oncogenic transformation.”
BackgroundSuzuki, S., Tanaka, T., Poyurovsky, M. V., Nagano, H., Mayama, T., Ohkubo, S., Lokshin, M., Hosokawa, H., Nakayama, T., Suzuki, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002459107 · Cited by 705 · cited 1×
“In comparison, function and regulation of LGA is not well studied, although it was recently shown to be linked to p53 pathway (13, 14).”
BackgroundRegulation of Glutaminase Activity and Glutamine Metabolism
Curthoys, N. P., & Watford, M. (1995) · Annual Review of Nutrition · doi:10.1146/annurev.nu.15.070195.001025 · Cited by 664 · cited 1×
“In glutaminolysis, mitochondrial glutaminase catalyzes the conversion of glutamine to glutamate (4), which is further catabolized in the Krebs cycle for the production of ATP, nucleotides, certain amino acids, lipids, and glutathione (2, 5).”
BackgroundInhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1666 · Cited by 513 · cited 1×
“BPTES selectively suppresses the growth of glioma cells (21) and inhibits the growth of lymphoma tumor growth in animal model studies (22).”
BackgroundRobinson, M. M., Mcbryant, S. J., Tsukamoto, T., Rojas, C., Ferraris, D. V., Hamilton, S. K., Hansen, J. C., & Curthoys, N. P. (2007) · Biochemical Journal · doi:10.1042/bj20070039 · Cited by 340 · cited 4×
“BPTES has attracted much attention as a selective, nontoxic inhibitor of KGA (15), and preclinical testing of BPTES toward human cancers has just begun (20).”
BackgroundResultInfluentialCassago, A., Ferreira, A. P. S., Ferreira, I. M., Fornezari, C., Gomes, E. R. M., Greene, K. S., Pereira, H. M., Garratt, R. C., Dias, S. M. G., & Ambrosio, A. L. B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112495109 · Cited by 285 · cited 2×
“Our findings are Thangavelu et al. PNAS | May 15, 2012 | vol. 109 | no. 20 | 7709 BI O CH EM IS TR Y further supported by two very recent reports on KGA isoform (GAC) (23, 24), although these studies lack full details owing to limitation of their electron density maps.”
ResultIdentification of two human glutaminase loci and tissue-specific expression of the two related genes
Aledo, J. C., Gómez-Fabre, P. M., Olalla, L., & Márquez, J. (2000) · Mammalian Genome · doi:10.1007/s003350010190 · Cited by 160 · cited 1×
“Humans express two glutaminase isoforms: KGA (kidney-type) and LGA (liver-type) from two closely related genes (6).”
BackgroundFull-Length Human Glutaminase in Complex with an Allosteric Inhibitor
DeLaBarre, B., Gross, S., Fang, C., Gao, Y., Jha, A., Jiang, F., Song J., J., Wei, W., & Hurov, J. B. (2011) · Biochemistry · doi:10.1021/bi201613d · Cited by 157 · cited 2×
“Our findings are Thangavelu et al. PNAS | May 15, 2012 | vol. 109 | no. 20 | 7709 BI O CH EM IS TR Y further supported by two very recent reports on KGA isoform (GAC) (23, 24), although these studies lack full details owing to limitation of their electron density maps.”
ResultLOBO, C., RUIZ-BELLIDO, M. A., ALEDO, J. C., MÁRQUEZ, J., NÚÑEZ DE CASTRO, I., & ALONSO, F. J. (2000) · Biochemical Journal · doi:10.1042/bj3480257 · Cited by 151 · cited 1×
“Inhibition of rat KGA activity by antisense mRNA results in decreased growth and tumorigenicity of Ehrlich ascites tumor cells (7), reduced level of glutathione, and induced apoptosis (8), whereas Myc, an oncogenic transcription factor, stimulates KGA expression and glutamine metabolism (5).”
BackgroundBrown, G., Singer, A. U., Proudfoot, M., Skarina, T., Kim, Y., Chang, C., Dementieva, I., Kuznetsova, E., González, C. F., Joachimiak, A., et al. (2008) · Biochemistry · doi:10.1021/bi800097h · Cited by 135 · cited 2×
“Notably, the putative serine-lysine catalytic dyad (286-SCVK-289), corresponding to the SXXKmotif of class D β-lactamase (17), is located in close proximity to the bound ligand.”
BackgroundLora, J., Alonso, F. J., Segura, J. A., Lobo, C., Márquez, J., & Matés, J. M. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04370.x · Cited by 134 · cited 1×
“Inhibition of rat KGA activity by antisense mRNA results in decreased growth and tumorigenicity of Ehrlich ascites tumor cells (7), reduced level of glutathione, and induced apoptosis (8), whereas Myc, an oncogenic transcription factor, stimulates KGA expression and glutamine metabolism (5).”
BackgroundColombo, S. L., Palacios-Callender, M., Frakich, N., De Leon, J., Schmitt, C. A., Boorn, L., Davis, N., & Moncada, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012362107 · Cited by 126 · cited 2×
“In addition, KGA is a substrate for the ubiquitin ligase anaphase-promoting complex/ cyclosome (APC/C)-Cdh1, linking glutaminolysis to cell cycle progression (12).”
BackgroundThe Solution Structure of FADD Death Domain
Jeong, E.-J., Bang, S., Lee, T. H., Park, Y. I., Sim, W.-S., & Kim, K.-S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16337 · Cited by 109
Disorders of glutamate metabolism
Kelly, A., & Stanley, C. A. (2001) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.1040 · Cited by 99 · cited 1×
“This could be the basis for abnormal cell growth in cancers and possibly other metabolic and neuronal disorders involving glutamate or ammonia as a main metabolite, such as hyperinsulinism/ hyperammonemia/hepatic encephalopathy and neurotransmission (25, 26).”
BackgroundRomero‐Gómez, M., Jover‐Cobos, M., Campo, J. A. D., Royo, J. L., Hoyas, E., Galán, J. J., Montoliu, C., Baccaro, E., Guevara, M., Córdoba, J., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-5-201009070-00002 · Cited by 79 · cited 1×
“This could be the basis for abnormal cell growth in cancers and possibly other metabolic and neuronal disorders involving glutamate or ammonia as a main metabolite, such as hyperinsulinism/ hyperammonemia/hepatic encephalopathy and neurotransmission (25, 26).”
BackgroundLow, B. C., Seow, K. T., & Guy, G. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004897200 · Cited by 47 · cited 1×
“performed as previously described (28, 29).”
Self-citationPan, C. Q., Liou, Y., & Low, B. C. (2010) · Journal of Cell Science · doi:10.1242/jcs.064162 · Cited by 27 · cited 1×
“performed as previously described (28, 29).”
Self-citationYoshimune, K., Shirakihara, Y., Wakayama, M., & Yumoto, I. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07523.x · Cited by 22 · cited 1×
“The previous crystal structures of microbial (Mglu) and Escherichia coli glutaminases show a conserved catalytic domain of KGA (16, 17).”
BackgroundGarber, K. (2010) · Nature Biotechnology · doi:10.1038/nbt0910-888 · Cited by 17 · cited 1×
“BPTES has attracted much attention as a selective, nontoxic inhibitor of KGA (15), and preclinical testing of BPTES toward human cancers has just begun (20).”
BackgroundTGF-β signaling and its effect on glutaminase expression in LLC-PK1-FBPase+cells
Andratsch, M., Feifel, E., Taylor, L., O’Hayre, M., Schramek, H., Curthoys, N. P., & Gstraunthaler, G. J. A. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00139.2007 · Cited by 13
Cited by
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer
Gross, M. I., Demo, S. D., Dennison, J. B., Chen, L., Chernov-Rogan, T., Goyal, B., Janes, J. R., Laidig, G. J., Lewis, E. R., Li, J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0870 · Cited by 1,068
“28 [21–37]”
Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation
Schiliro, C., & Firestein, B. L. (2021) · Cells · doi:10.3390/cells10051056 · Cited by 615
“Other genes implicated in playing a role in reprogramming glutamine metabolism include IDH1/2 [38], glutamate dehydrogenase (GDH) [39], pyruvate carboxylase (PC) [40], phosphatidylinositide 3-kinase (PI3K) [41], signal transducer and activator of transcription 1 (STAT1) [42,43], extracellular signal-regulated kinases…”
BackgroundGlutaminolysis as a target for cancer therapy
Jin, L., Alesi, G. N., & Kang, S. (2016) · Oncogene · doi:10.1038/onc.2015.447 · Cited by 459
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis
Xiang, Y., Stine, Z. E., Xia, J., Lu, Y., O’Connor, R. S., Altman, B. J., Hsieh, A. L., Gouw, A. M., Thomas, A. G., Gao, P., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75836 · Cited by 409
“The crystal structure of BPTES-bound GLS reveals that BPTES docks in the GLS tetramer interfaces, locking GLS in an off mode and disabling phosphate-dependent activation of the enzyme (24, 33, 34).”
Background
Metadata
- Authors
- Thangavelu, K., Pan, C. Q., Karlberg, T., Balaji, G., Uttamchandani, M., Suresh, V., Schüler, H., Low, B. C., & Sivaraman, J.
- Affiliations
- Departments of aBiological Sciences and
- National University of Singapore (SG)
- Structural Genomics Consortium (CA)
- Chemistry, National University of Singapore, Singapore 117543;
- Structural Genomics Consortium, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm SE-17177, Sweden; and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2012-04-26
- Volume
- 109
- Issue
- 20
- Pages
- 7705-7710
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3356676
- OpenAlex
- W2066800748
- Cited by
- 206
- References
- 29
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 16 · 2023: 12 · 2022: 17 · 2021: 16 · 2020: 21 · 2019: 16 · 2018: 18 · 2017: 11 · 2016: 19 · 2015: 12 · 2014: 14 · 2013: 13 · 2012: 5
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- Funders
- National Synchrotron Radiation Research Center
- National Institute of Biomedical Imaging and Bioengineering (P30EB009998)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- kidney-type glutaminase, glutaminolysis, cancer metabolism, BPTES, allosteric inhibition, MAPK/ERK pathway, EGF signaling, protein phosphorylation, MEK2, Raf-1, protein phosphatase 2A, U0126, conformational change, crystal structure, cell proliferation, glutamine addiction, small molecule inhibitors
- MeSH terms
- Allosteric Regulation, Crystallography, Glutaminase, Humans, Kidney, Models, Molecular, Mutation, Phosphorylation, Protein Binding, Protein Conformation, Sulfides, Thiadiazoles, Signal Transduction, Proto-Oncogene Proteins c-raf, MAP Kinase Signaling System, Cell Line, Tumor, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.